Efficacy and Safety of AQX-1125 in Unstable COPD

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo in subjects following exacerbations of Chronic Obstructive Pulmonary Disease (COPD) by targeting the SHIP1 (Src Homology 2-containing Inositol-5\'-Phosphatase 1) pathway.
Epistemonikos ID: 188433f2f6394659d61609006e9e0596d40272e1
First added on: May 11, 2024